About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
ASH 2021 Conference Coverage on VuMedi
Lymphoma
Leukemia
Myeloma
MDS and MPN
Benign Hematology
COVID-19 and Blood Cancers
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
E
ASH 2021 Highlights on Treatment Options for AL Amyloidosis Patients Ineligible for Autologous Transplantation
By
ASH 2021 Conference Coverage on VuMedi
FEATURING
Efstathios Kastritis
By
ASH 2021 Conference Coverage on VuMedi
FEATURING
Efstathios Kastritis
96 views
December 20, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Myeloma
05:27
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Sustained Improvement in HRQoL in Transplant-Ineligible Pat…
Feat.
A. Perrot
10:50
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Updates on the Efficacy and Safety of Cilta-Cel in R/R MM: …
Feat.
A. Jakubowiak
13:38
ASH 2021 Conference Coverage on VuMedi
2022 Updates on CAR T-Cell Therapy for Myeloma
Feat.
L. Anderson
05:57
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Update on the Impact of EPd on HRQoL for Patients With R/R …
Feat.
K. Weisel
05:25
ASH 2021 Conference Coverage on VuMedi
ASH 2021 on the Efficacy and Safety of Cilta-cel in Len-Refractory P…
Feat.
Y. C. Cohen
08:31
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Updated Results From the Phase I CRB-402 Study of the BCMA-…
Feat.
N. S. Raje
16:29
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Review of MRD in MM: Why, When, Where, and How?
Feat.
N. S. Raje
13:12
ASH 2021 Conference Coverage on VuMedi
ASH 2021: Addressing Current Questions and Controversies in the Mana…
Feat.
M. Gertz
07:41
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Update on Cilta-Cel for Triple-Class Exposed MM: Adjusted C…
Feat.
M. Mateos
04:34
ASH 2021 Conference Coverage on VuMedi
ASH 2021 on the Safety, Tolerability, PK/PD, and Preliminary Efficac…
Feat.
N. Shah
04:19
ASH 2021 Conference Coverage on VuMedi
ASH 2021: Risk of Infections With BCMA-Directed Immunotherapy in Mul…
Feat.
M. Mohan
07:00
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Updates on Outcomes in HR-MM Treated With Daratumumab
Feat.
F. van Rhee
13:23
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Highlights on Treatment Options for AL Amyloidosis Patients…
Feat.
E. Kastritis
09:07
ASH 2021 Conference Coverage on VuMedi
ASH 2021: Genomic and Immune Signatures Predict Sustained MRD Negati…
Feat.
E. Boyle
06:08
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Update on the Efficacy and Safety of Ruxolitinib and Steroi…
Feat.
J. Berenson
11:03
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Lecture on Clinical Outcomes of R/R MM Patients Following T…
Feat.
T. Mouhieddine
